BioSpace News Archive

LIXTE Biotechnology Holdings, Inc. announced that Bas van der Baan has been named as President and Chief Executive Officer of the Company, and as Vice Chairman of the Board of Directors, effective as of September 26, 2023.

CorMedix Inc. (Nasdaq: CRMD) today announced that management will be giving a company presentation at the Cantor Fitzgerald Global Healthcare Conference being held in New York City on September 26 – 28, 2023.

Sharps Technology, Inc. (the “Company”) (NASDAQ: “STSS” and “STSSW”) and Nephron Pharmaceuticals Corporation, (“Nephron”) a privately owned U.S. leader in contract manufacturing and 503B outsourcing, announce the signing of an Asset Purchase Agreement (APA) to acquire Nephron’s InjectEZ specialty syringe manufacturing facility.

Galmed Pharmaceuticals Ltd. announced today the allowance of a Japanese patent related to treatment of pulmonary and dermal fibrosis.

Arcturus Therapeutics Holdings Inc. (the announced today that Arcturus and the Cystic Fibrosis Foundation (CF Foundation) have extended their ongoing agreement.

Exo (pronounced “echo”), a medical imaging software and device company, today unveiled a category-redefining handheld ultrasound device, Exo Iris™, to put high-performance medical imaging into the hands—and pockets—of every caregiver.

Curio Bioscience today announced an expansion of its Curio Seeker product line with a larger format to deliver a more complete view of large biological structures, including human tissue samples, providing one hundred times more data compared to other whole transcriptome spatial analysis solutions.

Neogen Corporation (NASDAQ: NEOG) will issue its first-quarter earnings release before the opening of the market on Tuesday, October 10, 2023.

Munich, Germany. Therapyte GmbH, a Real-World Evidence and Advanced Analytics Company

Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for moderate Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials, announced today that an analysis of interim data from its OraGrowtH212 Trial was given as an oral presentation at the 2023 annual meeting of the European Society for Paediatric Endocrinology (ESPE),